Cargando…

Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection

Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrer-Batallé, Montserrat, Llop, Esther, Ramírez, Manel, Aleixandre, Rosa Núria, Saez, Marc, Comet, Josep, de Llorens, Rafael, Peracaula, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412429/
https://www.ncbi.nlm.nih.gov/pubmed/28420168
http://dx.doi.org/10.3390/ijms18040845
_version_ 1783233000340717568
author Ferrer-Batallé, Montserrat
Llop, Esther
Ramírez, Manel
Aleixandre, Rosa Núria
Saez, Marc
Comet, Josep
de Llorens, Rafael
Peracaula, Rosa
author_facet Ferrer-Batallé, Montserrat
Llop, Esther
Ramírez, Manel
Aleixandre, Rosa Núria
Saez, Marc
Comet, Josep
de Llorens, Rafael
Peracaula, Rosa
author_sort Ferrer-Batallé, Montserrat
collection PubMed
description Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that have resulted in the 4K score or the Prostate Health Index (PHI), and PSA glycoforms. In the present study, we have compared the PHI with our recently developed PSA glycoform assay, based on the determination of the α2,3-sialic acid percentage of serum PSA (% α2,3-SA), in a cohort of 79 patients, which include 50 PCa of different grades and 29 benign prostate hyperplasia (BPH) patients. The % α2,3-SA could distinguish high-risk PCa patients from the rest of patients better than the PHI (area under the curve (AUC) of 0.971 vs. 0.840), although the PHI correlated better with the Gleason score than the % α2,3-SA. The combination of both markers increased the AUC up to 0.985 resulting in 100% sensitivity and 94.7% specificity to differentiate high-risk PCa from the other low and intermediate-risk PCa and BPH patients. These results suggest that both serum markers complement each other and offer an improved diagnostic tool to identify high-risk PCa, which is an important requirement for guiding treatment decisions.
format Online
Article
Text
id pubmed-5412429
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54124292017-05-05 Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection Ferrer-Batallé, Montserrat Llop, Esther Ramírez, Manel Aleixandre, Rosa Núria Saez, Marc Comet, Josep de Llorens, Rafael Peracaula, Rosa Int J Mol Sci Article Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that have resulted in the 4K score or the Prostate Health Index (PHI), and PSA glycoforms. In the present study, we have compared the PHI with our recently developed PSA glycoform assay, based on the determination of the α2,3-sialic acid percentage of serum PSA (% α2,3-SA), in a cohort of 79 patients, which include 50 PCa of different grades and 29 benign prostate hyperplasia (BPH) patients. The % α2,3-SA could distinguish high-risk PCa patients from the rest of patients better than the PHI (area under the curve (AUC) of 0.971 vs. 0.840), although the PHI correlated better with the Gleason score than the % α2,3-SA. The combination of both markers increased the AUC up to 0.985 resulting in 100% sensitivity and 94.7% specificity to differentiate high-risk PCa from the other low and intermediate-risk PCa and BPH patients. These results suggest that both serum markers complement each other and offer an improved diagnostic tool to identify high-risk PCa, which is an important requirement for guiding treatment decisions. MDPI 2017-04-17 /pmc/articles/PMC5412429/ /pubmed/28420168 http://dx.doi.org/10.3390/ijms18040845 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ferrer-Batallé, Montserrat
Llop, Esther
Ramírez, Manel
Aleixandre, Rosa Núria
Saez, Marc
Comet, Josep
de Llorens, Rafael
Peracaula, Rosa
Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
title Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
title_full Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
title_fullStr Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
title_full_unstemmed Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
title_short Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
title_sort comparative study of blood-based biomarkers, α2,3-sialic acid psa and phi, for high-risk prostate cancer detection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412429/
https://www.ncbi.nlm.nih.gov/pubmed/28420168
http://dx.doi.org/10.3390/ijms18040845
work_keys_str_mv AT ferrerbatallemontserrat comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection
AT llopesther comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection
AT ramirezmanel comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection
AT aleixandrerosanuria comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection
AT saezmarc comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection
AT cometjosep comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection
AT dellorensrafael comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection
AT peracaularosa comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection